Novo Nordisk Loses GLP-1 Lead to Eli Lilly
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk held its annual summer party in August 2024 at the Roskilde fairgrounds outside Copenhagen, with the event roughly doubling in size to an estimated 20,000–23,000 attendees amid a hiring boom
- Novo Nordisk saw its stock hit an all-time high in June 2024, briefly valuing the Danish drugmaker at $658 billion and reclaiming the title of Europe's largest company by market capitalization
- Eli Lilly outmaneuvered Novo Nordisk and took control of the diet-drug market, according to MarketWatch, despite Novo's first-mover advantage with Ozempic
- Novo Nordisk developed Ozempic, described as the most lucrative new drug the world had ever seen, only to see its lead slip as competition intensified
- Denmark, a country of roughly 6 million people, saw its homegrown champion become the biggest company in Europe — a milestone now at risk as the competitive balance in GLP-1s shifts toward U.S.-based Eli Lilly
Why it matters: With Novo Nordisk valued at $658 billion at its June 2024 peak and Eli Lilly now controlling the diet-drug market, the contest between the two has reshaped Europe's corporate landscape — stripping Denmark of its flagship company at a time when policymakers are asking whether Europe can hold its own in the global pharma economy.
